Familial amyloidosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) No edit summary |
Farima Kahe (talk | contribs) |
||
| Line 11: | Line 11: | ||
'''Cardiac''' | '''Cardiac''' | ||
* [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. | * [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. They provide a quantitative assessment for [[Heart|cardiac]] damage and wall strain.<ref name="pmid21483018">{{cite journal |vauthors=Merlini G, Seldin DC, Gertz MA |title=Amyloidosis: pathogenesis and new therapeutic options |journal=J. Clin. Oncol. |volume=29 |issue=14 |pages=1924–33 |date=May 2011 |pmid=21483018 |pmc=3138545 |doi=10.1200/JCO.2010.32.2271 |url=}}</ref> | ||
:* Troponin I or Troponin T | :* Troponin I or Troponin T | ||
:* BNP and NT-proBNP | :* BNP and NT-proBNP | ||
'''Hepatic''' | '''Hepatic''' | ||
* Common [[Test|tests]] that are abnormal in [[liver function tests]] including: | * Common [[Test|tests]] that are abnormal in [[liver function tests]] including: | ||
| Line 29: | Line 25: | ||
'''Renal''' | '''Renal''' | ||
* Common [[Test|tests]] that are abnormal in renal function [[Test|tests]] including: | * Common [[Test|tests]] that are abnormal in renal function [[Test|tests]] including: | ||
| Line 38: | Line 33: | ||
'''Thyroid''' | '''Thyroid''' | ||
* Common [[Test|tests]] that are abnormal in thyroidal involvement of amyloidosis include: | * Common [[Test|tests]] that are abnormal in thyroidal involvement of amyloidosis include: | ||
| Line 45: | Line 39: | ||
'''Bone marrow''' | '''Bone marrow''' | ||
* Concurrent [[multiple myeloma]] can be found in [[Patient|patients]] with amyloidosis. In such cases [[laboratory]] [[Test|testing]] include<ref name="pmid24145344">{{cite journal| author=Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al.| title=Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 34 | pages= 4319-24 | pmid=24145344 | doi=10.1200/JCO.2013.50.8499 | pmc=4881366 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24145344 }} </ref>: | * Concurrent [[multiple myeloma]] can be found in [[Patient|patients]] with amyloidosis. In such cases [[laboratory]] [[Test|testing]] include<ref name="pmid24145344">{{cite journal| author=Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al.| title=Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. | journal=J Clin Oncol | year= 2013 | volume= 31 | issue= 34 | pages= 4319-24 | pmid=24145344 | doi=10.1200/JCO.2013.50.8499 | pmc=4881366 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24145344 }} </ref>: | ||
Revision as of 18:34, 30 October 2019
|
Familial amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Familial amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Familial amyloidosis laboratory findings |
|
Risk calculators and risk factors for Familial amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]
Overview
Laboratory findings in amyloidosis include elevated erythrocyte sedimentation rate, increased BUN level, serum creatinine, protein, casts, or fat bodies in urine. Serum troponin, B-type natriuretic peptide, and beta-2-microglobulin are prognostic markers for heart failure. Amyloid deposits can be identified histologically by Congo red staining and viewing under polarized light where amyloid deposits produce a distinctive 'apple green birefringence'. Alternatively, thioflavin T stain may be used. An abdominal fat pad aspiration, rectal mucosa biopsy, or bone marrow biopsy can help confirm the diagnosis. They reveal positive findings in 80% patients.
Laboratory Findings
Cardiac
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis. They provide a quantitative assessment for cardiac damage and wall strain.[1]
- Troponin I or Troponin T
- BNP and NT-proBNP
Hepatic
- Common tests that are abnormal in liver function tests including:
- AST
- ALT
- Total bilirubin
- Alkaline phosphatase
- Albumin
Renal
- Serum creatinine
- Urinary protein
- Glomerular filtration rate
- Albumin to creatinine ratio in the urine
Thyroid
- Common tests that are abnormal in thyroidal involvement of amyloidosis include:
- TSH
- Free T4
Bone marrow
- Concurrent multiple myeloma can be found in patients with amyloidosis. In such cases laboratory testing include[2]:
- Serum protein electrophoresis
- Immunoglobulin levels
- Serum free light chains
- Beta-2-microglobulin
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.
- ↑ Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR; et al. (2013). "Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis". J Clin Oncol. 31 (34): 4319–24. doi:10.1200/JCO.2013.50.8499. PMC 4881366. PMID 24145344.